Filing Details
- Accession Number:
- 0001144204-14-069538
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-11-18 16:36:50
- Reporting Period:
- 2014-11-14
- Filing Date:
- 2014-11-18
- Accepted Time:
- 2014-11-18 16:36:50
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1410098 | Cormedix Inc. | CRMD | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1189703 | M Cora Tellez | C/O Cormedix Inc. 745 Route 202-206, Suite 303 Bridgewater NJ US 08807 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, $0.001 Par Value Per Share | Acquisiton | 2014-11-14 | 11,086 | $1.52 | 63,386 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Common Stock, $0.001 Par Value Per Share | Stock Option (right to buy) | $2.05 | 2024-04-03 | 30,000 | 30,000 | Direct | |
Common Stock, $0.001 Par Value Per Share | Common Stock Warrants (right to buy) | $0.90 | 2014-01-08 | 2020-01-08 | 25,000 | 25,000 | Direct |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2024-04-03 | 30,000 | 30,000 | Direct |
2020-01-08 | 25,000 | 25,000 | Direct |
Footnotes
- The reporting person elected to receive common stock in lieu of cash for her board of director fees.
- These shares vest 1/3 on date of grant, 1/3 on first anniversary of date of grant and 1/3 on second anniversary of date of grant.
- On January 8, 2014, the reporting person acquired through a private placement, (i) 5,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share convertible into 10 shares of Common Stock, $0.001 par value per share (and which were converted to common stock on October 29, 2014); and (ii) a five-year warrant to purchase common Stock at an exercise price of $1.25 per share. The Series C-3 Non-voting Convertible Preferred Stock and warrants were purchased together at a purchase price of $10.00 per share. The warrant exercise price was decreased to $0.90 per share effective September 15, 2014.